Stay updated on INTRIGUE: Ripretinib vs Sunitinib in GIST Clinical Trial
Sign up to get notified when there's something new on the INTRIGUE: Ripretinib vs Sunitinib in GIST Clinical Trial page.

Latest updates to the INTRIGUE: Ripretinib vs Sunitinib in GIST Clinical Trial page
- Check7 days agoChange DetectedAdded Tainan, Taiwan as a study site. Removed the Tainan City, Taiwan listing and the government-funding status notice from the page.SummaryDifference0.2%

- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedNo significant changes were detected on the Study Details page for NCT03673501. The content, locations, and eligibility criteria appear unchanged.SummaryDifference0.2%

- Check50 days agoChange Detected- Updated version to v3.2.0 and removed the Gastrointestinal stromal tumor resource from Genetic and Rare Diseases Information Center. - Added a government funding lapse notice with operating-status guidance for users.SummaryDifference2%

- Check57 days agoChange DetectedUpdated the page version from v3.0.2 to v3.1.0 to reflect a newer release.SummaryDifference0.1%

- Check71 days agoChange DetectedUpdate to Revision: v3.0.2 from v3.0.1; removal of 'Back to Top' is a minor UI change and does not affect core content.SummaryDifference0.1%

- Check78 days agoChange DetectedThe web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.1%

Stay in the know with updates to INTRIGUE: Ripretinib vs Sunitinib in GIST Clinical Trial
Enter your email address, and we'll notify you when there's something new on the INTRIGUE: Ripretinib vs Sunitinib in GIST Clinical Trial page.